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SCIENTIFIC OPINION 
Scientific Opinion on the Tolerable Upper Intake Level of calcium 
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to re-evaluate the safety in use of calcium. The Panel was requested to consider if the Tolerable Upper 
Intake Level (UL) for calcium established by the SCF in 2003 (2,500 mg/day for adults, including pregnant and 
lactating women), which was based on different intervention studies of long duration in which total daily calcium 
intakes of 2,500 mg from both diet and supplements were tolerated without adverse effects, needed to be 
changed on the basis of new available evidence. A number of placebo controlled human intervention studies in 
adults published since then also showed that total daily calcium intakes of 2,500 mg from both diet and 
supplements are tolerated without adverse effects. The Panel considers that no relationship has been established 
between long-term calcium intakes from diet and supplements and increased risk of nephrolithiasis, 
cardiovascular disease or prostate cancer. No new data have become available which would require a revision of 
the UL for calcium for adults, including pregnant and lactating women, of 2,500 mg. No new data have become 
available which would allow the setting of a UL for infants, children or adolescents. Data from European 
populations indicate that intakes of calcium in high consumers among adult males can be close to the UL. 
Although available data do not allow the setting of a UL for infants, children or adolescents, no risk has been 
identified with highest current levels of calcium intake in these age groups. © European Food Safety Authority, 
2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to re-evaluate the safety in use of calcium and to provide, if necessary, revised 
Tolerable Upper Intake Levels (ULs) of calcium for all relevant population groups. 
Calcium is important for the maintenance of healthy teeth and bones, cell signalling, coagulation, 
muscle contraction, neural transmission and many other functions. Calcium is the fifth most abundant 
element in the human body. Some 99 % of the total calcium of the body is located in bones and teeth, 
mostly as calcium hydroxyapatite. Bone mineral provides structure and strength to the body, and a 
reservoir of calcium that helps to maintain a constant concentration of calcium in the blood. 
Foods vary widely in calcium content. The best sources are milk and milk products, which provide 
about 45 to 70 % of the dietary calcium in European diets. Some plants, drinking and mineral water, 
and food supplements are also good sources of well absorbable calcium. 
A number of potential adverse effects of excessive calcium intakes have been proposed. These 
include hypercalciuria, deterioration of kidney function, kidney stone formation, the milk-alkali 
syndrome (MAS), vascular calcification, increased risk of cardiovascular disease and increased risk 
of prostate cancer. 
The SCF (2003) based the derivation of a UL for calcium on the evidence of different intervention 
studies of long duration, some of which were placebo controlled, in which total daily calcium intakes 
of 2,500 mg from both diet and supplements were tolerated without adverse effects. Because of the 
abundance of data, the application of an uncertainty factor was considered unnecessary. A UL of 
2,500 mg of calcium per day from all sources was proposed for adults, and for pregnant and lactating 
women.  
A number of placebo controlled human intervention studies in adults published since then also show 
that total daily calcium intakes of 2,500 mg from both diet and supplements are tolerated without 
adverse effects.  
The Panel notes that new case reports have become available on consumption of calcium supplements 
and the CAS/MAS syndrome. However, the Panel considers that no dose-response relationships can 
be derived from these.  
The Panel considers that no relationship has been established between long-term calcium intakes 
from diet and supplements and increased risk of nephrolithiasis, cardiovascular disease or prostate 
cancer. 
The Panel concludes that no new data have become available which would require a revision of the 
UL for calcium for adults, including pregnant and lactating women, of 2,500 mg, and that no new 
data have become available which would allow the setting of a UL for infants, children or 
adolescents.  
Data from European populations indicate that intakes of calcium in high consumers among adult 
males can be close to the UL. Although available data do not allow the setting of a UL for infants, 
children or adolescents, no risk has been identified with highest current levels of calcium intake in 
these age groups. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Calcium has been assessed in the past by the Scientific Committee on Food. In the Opinion on the 
Tolerable Upper Intake Level (UL) of calcium of 4 April 2003 an UL was established for adults of 
2500mg of calcium per day for calcium intake from all sources. The Committee could not derive an 
UL for children and adolescents due to insufficient data.  
On 30 November 2010, the American Institute of Medicine (IoM) published a report on “Dietary 
Reference Intakes for Calcium and Vitamin D”. In this report, the IoM proposes new reference values 
and UL values for calcium which, as stated in the report “are based on much more information and 
higher-quality study results than were previously available”.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Commission 
asks the European Food Safety Authority to: 
- re-evaluate the safety in use of calcium,  
- if necessary, provide revised tolerable upper intake levels, that are unlikely to pose a risk of 
adverse health effects, for calcium for all relevant population groups. 
Tolerable Upper Intake Level of calcium 
 
EFSA Journal 2012;10(7):2814 5 
ASSESSMENT 
1. Introduction 
Calcium is important for the maintenance of healthy teeth and bones, cell signalling, coagulation, 
muscle contraction, neural transmission and many other functions. Calcium is the fifth most abundant 
element in the human body. Some 99 % of the total calcium of the body is located in bones and teeth, 
mostly as calcium hydroxyapatite. Bone mineral provides structure and strength to the body, and a 
reservoir of calcium that helps to maintain a constant concentration of calcium in the blood. 
In 2003, the Scientific Committee on Food (SCF) established a Tolerable Upper Intake Level (UL) of 
calcium for adults, including pregnant and lactating women, of 2,500 mg/day. This UL was based on 
different long-term intervention studies in which a total daily intake of 2,500 mg of calcium/day from 
all sources (diet and supplements) was tolerated without adverse effects. The Committee was unable 
to derive a UL for children and adolescents from the very few data available from intervention 
studies, and it was considered inappropriate to derive such age-specific ULs via extrapolation from 
data collected in older age groups. 
The UL for calcium of the SCF (2003) was the same as that from the US Institutes of Medicine (IoM, 
1997), which was based on a LOAEL of 4,000-5,000 mg/day identified by using the milk alkali 
syndrome as the critical endpoint and applying an uncertainty factor of 2 because of observed 
associations between calcium intake and the potential hazard of kidney stones, hypercalciuria, and 
interference of dietary calcium with the bioavailability of some minerals in vulnerable populations. 
The IoM also defined the same UL of 2,500 mg of calcium/day for adults >70 years of age, for 
children and adolescents 1-18 years of age, and for pregnant and lactating women, but could not 
establish a UL for infants. 
In 2011, the IoM published its re-assessment of the UL for calcium, which for adults ≥51 years old 
was based on a LOAEL of 2,000 mg of calcium/day with nephrolithiasis as the critical endpoint 
(Jackson et al., 2006). No uncertainty factor was applied. For adults 19 to 50 years of age, the UL was 
the same as in 1997 and was derived by interpolation between the UL for older adults and the new UL 
of 3,000 mg for children aged 9-13 years and adolescents aged 14-18 years. This latter value was set 
taking into account a presumably higher need of, and consequently a higher tolerance for, calcium in 
the age group 9-18 years in connection with the pubertal growth spurt. A UL of 1,500 mg of 
calcium/day was derived from a NOAEL of 1,750 mg/day observed in one intervention study on 
infants aged 2.5 to 5 months at baseline and 9 months at the end of the intervention (Dalton et al., 
1997; Sargent et al., 1999). Uncertainty factors of 2 and 1.2 were applied to adjust for the weight 
increment during the intervention and the results were rounded up to ULs of 1,000 mg/day for infants 
aged 0-6 months and of 1,500 mg/day for infants aged 6-12 months, respectively. No new data were 
available for the age group 1-8 years and the UL of 2,500 mg/day was kept. For pregnant and lactating 
women, the age-specific UL for adolescents aged 14-18 years of 3,000 mg/day and the UL of 
2,500 mg/day for women >19 years of age were considered adequate.  
The Panel was requested to consider whether the UL for calcium established by the SCF in 2003 
needed to be changed on the basis of new available evidence. 
2. Dietary Intake 
2.1. Food sources including dietary supplements 
Foods vary widely in calcium content. The best sources are milk (120 mg/100 g) and milk products 
(up to about 1,100 mg/100 g), from which about 32 % of calcium is absorbable (Weaver, 2001). In 
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European diets, about 45 to 70 % of the dietary calcium intake is provided by dairy products 
(Guéguen and Pointillart, 2000; IUNA (Irish Universities Nutrition Alliance), 2001). Some plants are 
good sources of well absorbable calcium, for example brassica, almonds and dried apricots. However, 
some vegetables (rhubarb, spinach) contain considerable amounts of calcium which is poorly 
absorbed because of a high content in oxalate, which forms sparingly soluble calcium oxalate. 
Drinking water and mineral waters (>150 mg calcium/L) can also be good sources of absorbable 
calcium. 
In the European Union, the following forms of calcium are authorised for addition to foods and for 
use in food supplements (Annex II of the Regulation (EC) No 1925/2006
4
 and Annex II of Directive 
2002/46/EC
5
): carbonate, chloride, citrate malate, gluconate, glycerophosphate, lactate, hydroxide, 
oxide, acetate, L-ascorbate, bisglycinate, salts of citric acid, pyruvate, salts of orthophosphoric acid, 
succinate, L-lysinate, malate, L-pidolate, L-threonate, sulphate.  
2.2. Dietary intakes  
Mean intakes of calcium in European countries vary according to sex, age, and supplementation 
habits (Appendices A and B). There is a large diversity in the methodology used to assess the 
individual intakes of children, adolescents and adults. These differences in dietary assessment 
methods make direct comparisons difficult. Data from Poland based on a single 24-h recall have been 
listed in Appendices A and B for completeness, but have not been considered in the text. Age 
classifications may not be uniform and comparability is also hindered by differences in food 
composition tables used for the conversion of food consumption data to nutrient intake data 
(Deharveng et al., 1999). Although these differences have an impact on the accuracy of 
between-country comparisons, the data presented give a rough overview of average calcium intakes 
and intakes in high consumers in a number of European countries.  
2.2.1. Adults 
Mean calcium intakes from food only were between 623 mg/day (Belgium, 75 years) and 
1,374 mg/day (Denmark, men, 18-24 years), and median intakes were within this range. Available 
values for high percentiles of intake were between 1,045 mg/day (Spain, P95, women, 18-64 years) 
and 2,422 mg/day (Germany, P95, men, 19-24 years). Mean calcium intakes in the surveys 
considering food and food supplements combined were within these ranges, as well as values for the 
highest percentiles of calcium intake. 
2.2.2. Infants (≤1 year) 
Mean calcium intakes from food were available from one country only (The Netherlands) and varied 
between 730 mg/day (0.75 years) and 824 mg/day (1 year). The value for the high percentile was 
1,085 mg/day (P90, 1 year). Mean calcium intakes for the entire sample and for the highest percentiles 
of consumption in the only study (Finland) which considered food and food supplements together 
were within these ranges. 
2.2.3. Children (generally between 1 and 14 years) 
For young children (0-3 years), mean calcium intakes from food were between 664 mg/day (Italy, 
0-<3 years) and 1,024 mg/day (Greece, 1-5 years). Values for the high percentiles of calcium intake 
                                                     
4 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26-38. 
5 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51-57. 
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were between 1,070 mg/day (Italy, P95, 0-3 years, including fortified food) and 1,392 mg/day 
(Greece, P90, 1-5 years). Mean calcium intakes for the entire sample and for the highest percentiles of 
consumption in the surveys considering food and supplements together were within these ranges. 
For older children (about 3-14 years) mean calcium intakes from food were between 804 mg/day 
(Ireland, girls, 5-12 years; United Kingdom, 4-10 years) and 1,072 mg/day (Denmark, aged 
4-14 years), and median intakes were within that range. Values for the high percentiles of intake were 
between 1,123 mg/day (Spain, P95, 4-10 years) and 1,776 mg/day (Denmark, P95, 4-14 years). 
Calcium intakes were slightly higher in food surveys considering food and food supplements together. 
In these surveys, mean calcium intakes were between 724 mg/day (The Netherlands, 4-6 years) and 
1,103 mg/day (Finland, boys, 6 years), and median intakes were within that range. Values for the high 
percentiles of intake varied between 1,151 mg/day (Spain, P95, 4-10 years, including fortified food) 
and 1,623 mg/day (The Netherlands, P95, boys, 9-13 years). 
2.2.4. Adolescents (generally between 10 and 18 years) 
Mean calcium intakes from food varied from 734 mg/day (Ireland, girls, 13-17 years) to 1,337 mg/day 
(Germany, 12-17 years). The two available median values were within that range. Values for the high 
percentiles of intake varied between 1,231 mg/day (Spain, P95, 11-17 years) and 2,400 mg/day 
(Germany, P95, 12-17 years).  
Mean calcium intakes from food and supplements combined were between 786 mg/day (United 
Kingdom, 11-18 years) and 1,396 mg/day (Germany, 12-17 years, including fortified food). Available 
median intakes were within that range. The values for the high percentiles varied between 
1,267 mg/day (Spain, P95, 11-17 years, including fortified food) and 2,515 mg/day (P95, Germany, 
12-17 years, including fortified food). 
3. Hazard identification 
3.1. Calcium physiology and homeostasis  
Calcium homeostasis is under endocrine and genetic control. Systemic and local factors regulate 
intestinal absorption, influx and efflux from bone, and calcium excretion and re-absorption by the 
kidney. Because of this regulatory network, there is no biomarker for calcium status. 
3.1.1. Serum calcium and its regulation 
Calcium is present in the blood in three different forms: as free Ca
2+
 ions, bound to protein (about 
45 %), and complexed to citrate, phosphate, sulphate and carbonate (about 10 %). Calcium in the 
blood (and in extracellular fluid) is kept constant at 2.5 mmol/L (range 2.25-2.6 mmol/L), but it is 
ionised calcium (between 1.1-1.4 mmol/L) which is controlled by the interrelated action of three 
hormones, namely parathyroid hormone (PTH), 1,25-dihydroxycholecalciferol (1,25-(OH)2-D) and 
calcitonin. The first two determine how much Ca
2+
 moves out of or into the body, whilst PTH 
determines how Ca
2+ 
moves between the extracellular fluid and bone.  
A decrease in serum concentrations of Ca
2+ 
induces the release of PTH via the calcium-sensing 
receptor (CaSR) which is located on the cell surface of the parathyroid glands. The PTH stimulates 
1,25-(OH)2-D synthesis in the kidney, bone resorption, and renal re-absorption of calcium (Perez et 
al., 2008). Synthesis of 1,25-(OH)2-D is also stimulated by low serum phosphorus concentrations and 
decreases with high phosphorus concentrations. An increase in serum concentrations of Ca
2+ 
inhibits 
PTH secretion via the CaSR and 1,25-(OH)2-D synthesis, and stimulates calcitonin secretion by the 
parafollicular C cells of the thyroid gland. Other locations of the CaSR include the intestine, kidney, 
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thyroid gland, lung, brain, skin, bone marrow, and osteoblasts. According to population-based 
genome-wide association studies, individual serum calcium concentrations within the normal range 
are influenced by some single-nucleotide polymorphisms of the CaSR gene (O'Seaghdha et al., 2010; 
Riccardi and Brown, 2010). 
Several genetic disorders have been described where this homeostatic regulation is disturbed and 
hypercalcaemia results. The latter is considered to be a consequence of either due to loss-of-function 
mutations of CYP24A1 which encodes 25-hydroxyvitamin D 24-hydroxylase leading to idiopathic 
infantile hypercalcaemia (OMIM 143880) , or inactivating mutations of the CaSR gene (Schlingmann 
et al., 2011). Such mutations can result in either neonatal severe primary hyperparathyroidism (OMIM 
239200) or familial hypocalciuric hypercalcaemia (OMIM 145980). Rarely, inactivating auto-
antibodies against CaSR cause hypocalciuric hypercalcaemia (Riccardi and Brown, 2010). Activating 
mutations of the CaSR gene can be the cause of autosomal dominant hypoparathyroidism (OMIM 
601298) with hypocalcaemia and hypercalciuria, or of the Bartter syndrome type V. 
Hypercalcaemia is defined by serum calcium concentrations >2.75 mmol/L (11 mg/dL). Values used 
for the diagnosis of hypercalcaemia may change across laboratories and will be defined in this 
Opinion according to the cut-off selected by the authors in each individual study. The most common 
causes of hypercalcaemia include malignant tumours, hyperparathyroidism of different aetiology, and 
less frequently excessive calcium and/or vitamin D intakes. Clinical symptoms of persistent 
hypercalcaemia are fatigue, muscular weakness, anorexia, nausea, vomiting, constipation, tachycardic 
arrhythmia, soft tissue calcification, failure to thrive and weight loss. Hypercalcaemia can lead to 
hypercalciuria when the renal capacity of calcium re-absorption is exceeded, and to renal 
concentration defects resulting in polyuria through activation of the renal CaSR.  
Consequences of severe chronic hypercalcaemia are nephrolithiasis and impairment of kidney 
function, resulting in loss of the concentrating ability of the kidney (i.e., a decrease in salt and water 
reabsorption), and in volume and salt depletion. Chronic hypercalcaemia may also lead to 
calcification of soft tissues (e.g., nephrocalcinosis and vascular calcification), particularly when 
phosphorus concentrations in the blood are also high, as in renal insufficiency. The age-related 
decrease in urinary calcium excretion and renal function increases the sensitivity of older people to 
excess calcium intakes. 
3.1.2. Calcium absorption in the intestine 
Calcium must be in a soluble form or bound to soluble organic molecules to be absorbable. 
Depending on solubility, chemical form and other factors of the food, the fractional absorption of 
dietary calcium in adults is around 25 % (range 10 to 40 %). Fractional absorption decreases with 
high calcium content of diets and increases with low-calcium diets. This adaptation is modulated by 
PTH and 1,25-(OH)2-D in response to lower or higher serum calcium concentrations. Fractional 
calcium absorption is highest (up to 60%) in infancy (Abrams et al., 1997), declines thereafter to rise 
again before puberty, and declines after puberty to the adult value of 25 %. During pregnancy calcium 
absorption is twice as high (Moser-Veillon et al., 2001). Dietary factors also modulate calcium 
absorption. Most calcium salts used in fortified foods or dietary supplements are absorbed to a similar 
extent as calcium from dairy foods. A difference in the kinetics of calcium taken as a supplement and 
calcium taken with food is manifested in earlier and higher rises of serum calcium with supplemental 
calcium than with calcium ingested with food, whilst the total amount of calcium absorbed may be 
enhanced with food (Heaney et al., 1989). Significant differences in the time course of rises in serum 
calcium and reactive decreases in serum PTH concentrations following the consumption of different 
calcium salts (formate >> citrate > carbonate) in the fasting state have been observed (Hanzlik et al., 
2005). The clinical significance with respect to calcium uptake into bone and excretion of excess 
calcium into urine is not clear. Ionised calcium in serum following the ingestion of 1,000 mg of 
calcium as a supplement just before a meal by healthy subjects rose in 20 of 40 trials above the upper 
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limit of normal (specified as 1.28 mmol/L) within two to four hours, and was accompanied by a 
significant increase in calcium excretion in the urine and by an increase of the calcium/creatinine ratio 
by up to 0.13 (Reid et al., 1986). This finding indicates that rapidly absorbed calcium can transitorily 
lead to increased concentrations of serum and urinary calcium. The bulk of unabsorbed calcium forms 
complexes with bile acids, free fatty acids, oxalic acid and phytic acid, and excreted in the faeces 
(Heaney, 2002).  
There are two main mechanisms for calcium transport in the intestine: an active transcellular process 
and a passive paracellular process. Both are regulated by hormones, nutrients and other factors. 
Active transcellular transport in the small intestine is saturable and regulated by dietary intake and the 
needs of the body. The efficiency of this transport improves with diets low in calcium and in 
situations of increased need for calcium (e.g. growth, pregnancy and lactation), and it decreases with 
age. Regulation of the uptake of calcium ions (Ca 
2+
) at the apical side of the epithelium, and the 
release at the basolateral membrane, involves epithelial Ca
2+ 
channels TRPV5 and TRPV6 (which are 
also expressed in the kidney and other organs), calbindins, the plasma-membrane Ca-ATPase 




 exchanger (NCX1), whose activation and/or expression is under the 
control of 1,25-(OH)2-D by binding to the vitamin D receptor (VDR). 
Passive para-cellular diffusion through the tight junctions of the intestinal epithelium, particularly of 
the jejunum and ileum, follows down an electrochemical gradient together with water, sodium and 
glucose, which is determined by the concentration of soluble calcium in the gut lumen. Passive 
para-cellular diffusion becomes important when dietary calcium is high and the trans-cellular pathway 
is down-regulated. This process is independent of age (Bronner, 1992).  
3.1.3. Renal excretion and re-absorption of calcium 
The majority of calcium absorbed is stored in the skeleton. Excess of absorbed calcium is excreted in 
urine, faeces and sweat. Calcium balance is positive in healthy children, adolescents and young adults 
before bone growth and bone modelling cease. Renal calcium excretion is the net result of glomerular 
filtration and tubular passive (collecting duct) or active (proximal tubule, loop of Henle, distal tubule) 
reabsorption (normal over 98 % of the filtered load). Active transport is under the control of PTH, 
calcitonin and 1,25-(OH)2-D, the levels of which are set via the CaSR by the calcium concentrations 
in extracellular fluid (Hoenderop et al., 2002). Average 24-h excretion of calcium is 40 mg in young 
children, 80 mg in prepubertal children and reaches about 150-200 mg in healthy adults. Small 
changes in the levels of Ca
2+ 
which is filtrated into the urine can lead to substantial changes in urinary 
calcium. Below a serum calcium concentrations of 2 mmol/L, little (if any) calcium is excreted in the 
urine (<30 mg/24 h). The maximum amount of calcium which can be excreted by healthy humans is 
about 1,000 mg/24 h. Higher amounts are associated with the risk of calcium deposition in the renal 
tissue or with the formation of kidney stones because urine is supersaturated with calcium and 
phosphate. Stone formation and renal calcification are enhanced by an alkaline environment.  
Urinary calcium excretion is increased by dietary sodium intake (30 to 40 mg of calcium excreted per 
every two grams of dietary sodium) (Matkovic et al., 1995) and in chronic metabolic acidosis 
(Bushinsky, 2001). Calcium excretion rises with excess dietary protein intake (by 0.5 mg for each 
gram of dietary protein, when intake is >47 g/day) (Walker and Linkswiler, 1972; Whiting et al., 
1998). 
Hypercalciuria is defined by a calcium excretion >0.3 mg/mg creatinine in 24-hour urine of adults, by 
a calcium excretion >250 mg/day in women and >275-300 mg/day in men, or by a calcium excretion 
>4 mg/kg bw/day for both men and women. Calcium/creatinine ratios in urine are higher in infancy 
and decrease with age. In randomly collected urine samples, calcium/creatinine ratios of 0.9, 0.6, 0.42 
and 0.22 have been reported for ages <7 months, 7-18 months, 19 months to 6 years, and adults, 
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respectively (Sargent et al., 1993). Calcium/creatinine ratios may differ somewhat in different 
populations because of differences in dietary habits, sunshine exposure, drinking water composition 
and ethnicity. An increase in the calcium/creatinine ratio in a random urine sample can be an 
incidental occurrence only.  
Chronic hypercalciuria may be the consequence of increased intestinal absorption of calcium 
(absorptive) or of decreased renal calcium reabsorption (resorptive). Causes of chronic hypercalciuria 
include excessive calcium intake (without accompanying hypercalcaemia), excessive vitamin D 
intake, hyperparathyroidism, hyperthyroidism, renal tubular acidosis, sarcoidosis or malignant tumors. 
Idiopathic (primary) hypercalciuria is characterised by the lack of concomitant hypercalcaemia. 
Pregnant women are often hypercalciuric from the 12
th
 gestational week onwards even with “normal” 
calcium intakes. The hypercalciuria results from the doubling of intestinal calcium absorption in early 
pregnancy, which leads to positive calcium balance (Heaney and Skillman, 1971). 
Persistent hypercalciuria is associated with decreased bone mineral density and higher risk of kidney 
stone formation, particularly in subjects with idiopathic hypercalciuria (Audran et al., 1991; Bataille 
et al., 1991). Kidney stones affect more than 5 % of the population in Europe, and up to 20-40 % of 
patients with calcium containing stones (about 80 % of kidney stones) have idiopathic hypercalciuria. 
As stones form in urine that is supersaturated, high concentrations of calcium (and oxalate) in urine, 
rather than the total amount of calcium excreted, increase the risk of nephrolithiasis (kidney stones). 
Other dietary risk factors for nephrolithiasis include low fluid intakes and high intakes of protein, salt, 
sucrose, alcohol and oxalate. Pregnancy is associated with an increased risk of kidney stone 
formation. 
3.2. Adverse effects of excess calcium intake 
A number of potential adverse effects of excessive calcium intakes have been proposed. These 
include hypercalciuria, deterioration of kidney function, kidney stone formation, the milk-alkali 
syndrome (MAS), vascular calcification, increased risk of cardiovascular disease and increased risk of 
prostate cancer (IoM, 2011).  
3.2.1. Milk-alkali syndrome/calcium-alkali-syndrome  
The adverse effects of combined therapy for peptic ulcers with milk and absorbable antacids (mostly 
sodium bicarbonate or calcium carbonate) were named collectively MAS (Burnett et al., 1949; Cope, 
1936). Milk-alkali syndrome is characterised by metabolic alkalosis and hypercalcaemia with 
dehydration, renal failure, nephrocalcinosis and nephrolithiasis in variable combinations and severity. 
The SCF (2003) compiled case reports from 82 patients (24-95 years) with MAS, in which total 
calcium intakes were generally inadequately documented but reported to range between 400 and 
23,000 mg/day. Milk-alkali syndrome was not observed in the course of a number of intervention 
studies which involved between 11 and 2,295 individuals (children, pregnant and pre- or 
perimenopausal women, elderly subjects), tested the effects of calcium supplements (500 to 
2,000 mg/day) on different outcomes, and lasted between 12 weeks to four years (SCF, 2003).  
Since then the therapy including milk for peptic ulcers has become obsolete but the syndrome has 
been increasingly observed with high intakes of supplemental calcium carbonate and MAS has been 
re-named calcium-alkali-syndrome (CAS) (Patel and Goldfarb, 2010). On the basis of 14 cases 
(2004-2010) reporting elevated serum calcium (2.64-6.43 mmol/L) and creatinine concentrations in 
males and females (35-81 years) consuming calcium carbonate at doses >1,000-44,000 mg/day, the 
IoM (2011) concluded that supplemental intakes of calcium carbonate 3,000 mg/day were 
hazardous. Duration of supplementation was only reported in seven cases (from weeks to 19 years).  
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Extensive calcification of renal convoluted tubular cells and the tubular lamina have been described in 
kidney biopsies of patients with MAS or CAS, and which in severe cases were associated with 
interstitial fibrosis, areas of inflammatory changes and peri-glomerular fibrosis. The extent of calcium 
deposition was proportional to renal dysfunction. Calcium deposits in the cornea and conjunctiva, and 
less commonly in peri-articular tissue, subcutaneous tissue, the central nervous system, liver, adrenal 
glands, bone and lungs, have also been observed in chronic cases of MAS (Medarov, 2009). 
The Panel notes that supplemental alkaline calcium intakes at doses >1,000 mg/day may increase the 
risk of CAS, but these case reports do not allow an estimation the amount of calcium or the duration 
of the treatment at which the risk increases. 
A decrease in calcium excretion or in kidney function (e.g. in old age), an increase in calcium 
re-absorption (e.g. thiazide diuretics), or conditions leading to metabolic alkalosis (e.g. hyperemesis 
in pregnancy or bulimia) are risk factors for developing CAS when individuals are taking alkaline 
calcium supplements (Medarov, 2009).  
3.2.2. Hypercalciuria, kidney function and kidney stones 
3.2.2.1. Adults 
The SCF (2003) reported on a higher frequency (compared to placebo) of incidental hypercalciuria 
(>350 mg/day) in post-menopausal women consuming calcium supplements (1,600 mg/day), in 
addition to dietary calcium intakes of about 800 mg/day, for four years. No subject receiving calcium 
supplements developed kidney stones, nephrocalcinosis or a reduction in glomerular filtration rate 
(Riggs et al., 1998). A trend for an increase in serum creatinine (by 1.2 μmol/L) with total calcium 
intakes of 2-3 g/day had been observed in a study involving 130 peri-menopausal women (Elders et 
al., 1994), whereas no effect was reported in 46 women aged 50-70 years at comparable calcium 
intakes (Schaafsma et al., 2002). It was unclear whether compromised glomerular function as 
indicated by increases in serum creatinine could have been attributed to high calcium intakes in the 
first study.  
The effect of different doses of calcium on hypercalciuria and/or kidney function has not been 
systematically investigated, and no new data have become available since 2003.  
The SCF (2003) also reported no increased risk of kidney stones in approximately 5,000 subjects 
(from different intervention studies) who received between 500 and 2,000 mg calcium/day as a 
supplement in addition to 300 to 1,800 mg of calcium/day from the diet (total intakes between 
1,300 and 3,000 mg calcium/day) during three months to four years. None of these studies were 
designed to investigate the effects of calcium supplements on kidney stone formation. In two 
prospective cohort studies with 45,619 men aged between 40 and 75 years followed over four years 
(the Health Professionals Follow-up Study, Curhan et al., 1993) and 91,731 women aged between 
34 and 59 years followed over 12 years (the Nurses' Health Study I, Curhan et al., 1997), without 
kidney stones at the beginning of the observation period, total calcium intakes >1,050 mg/day in men 
and >1,100 mg/day in women decreased the risk of kidney stone formation by approximately 35 % 
compared to lower intakes. In both studies, an inverse association was reported between dietary 
calcium and risk of kidney stones after adjustment for confounders, whereas calcium supplements in 
daily amounts below 100 mg increased the risk for stone formation by 20 % in women, with no 
further increase in the relative risk at higher intakes. In a population-based study which involved 
1,309 women aged 20 to 92 years, women with kidney stones (n=44) ingested on average 250 mg less 
calcium per day than women without stones (840 vs 1,070 mg/day). Calcium supplements were not 
associated with the risk of kidney stone formation (Sowers et al., 1998). 
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The SCF (2003) concluded that both observational studies on the relationship between total calcium 
intake and kidney stone incidence and intervention studies with calcium supplements did not allow an 
estimation of the calcium intake on a population basis which would promote kidney stone formation.  
A longer follow-up of the Health Professionals Study (Taylor et al., 2004) and results from a new 
Nurses’ Health Study II (Curhan et al., 2004) have been published since then. In addition, the IoM 
(2011) established the UL for adults aged >51 years (LOAEL of 2,000 mg of calcium/day with 
nephrolithiasis as the critical endpoint) on the basis of a secondary analysis of the Women’s Health 
Initiative (WHI) intervention trial (Jackson et al., 2006), for which a subsequent publication has 
become available (Wallace et al., 2011). 
In the 14-year follow-up of the Health Professionals Study (Taylor et al., 2004), self-administered 
food frequency questionnaires (FFQs) were used to assess dietary (and supplemental) intakes at 
baseline and every four years in 45,619 men aged 40 to 75 years without history of nephrolithiasis. A 
total of 1,473 incident symptomatic kidney stones were documented. After adjusting for relevant risk 
factors, a higher dietary calcium intake was associated with a reduced risk of kidney stones (RR 0.69, 
95 % CI 0.56-0.87, for men in the highest vs. the lowest quintile of calcium intake) in men aged 
<60 years. Median calcium intakes from the diet were 503 mg/day in the lowest and 1,194 mg/day in 
the highest quintiles, respectively. There was no association between dietary calcium and stone 
formation in men aged 60 years. Supplemental calcium intake was not associated with risk of 
developing kidney stones.  
Similarly, in the eight-year follow-up of the Nurse’s Health Study II (Curhan et al., 2004), 
self-administered food frequency questionnaires were used to assess dietary (and supplemental) 
intakes at baseline and at four years of follow-up in 96,245 female participants aged 27 to 44 years 
with no history of kidney stones. A total of 1,223 incident symptomatic kidney stones were 
documented. After adjusting for relevant risk factors, a higher dietary calcium intake was associated 
with a reduced risk of kidney stones (RR 0.73, 95 % CI 0.59-0.90, for women in the highest vs. the 
lowest quintile of calcium intake). Calcium intakes from diet were <626 mg/day in the lowest and 
>1,129 mg/day in the highest quintiles, respectively. Supplemental calcium intake was not associated 
with risk of kidney stone formation.  
The Panel notes that dietary calcium intakes in the range of the most recent dietary recommendations 
do not promote kidney stone formation on a population basis. The Panel also notes that calcium 
supplements have not been associated with an increased risk of kidney stones in large prospective 
cohort studies. 
In the Women’s Health Initiative trial (Jackson et al., 2006), 36,282 post-menopausal women aged 
50 to 79 years (mean age 62 years) were randomly assigned to consume with meals either a placebo 
(n=18,106) or 1,000 mg of elemental calcium (calcium carbonate) with 10 μg (400 IU) of vitamin D3 
per day (n=18,176) for an average period of seven years. Hypercalcaemia and kidney stones were 
among the exclusion criteria. The primary outcomes were bone fractures and measures of bone 
density. Subjects were allowed to continue the use of personal supplements up to 1,000 mg of calcium 
and up to 12.5 µg of vitamin D per day. Mean baseline intake (diet and non-trial supplements) of 
calcium was approximately 1,150 mg/day, and mean baseline intake of vitamin D was about 9 µg/day. 
About 40 % of the subjects consumed >1,200 mg calcium/day at baseline and 29 % consumed 
personal supplements with >500 mg calcium daily. Compliance ( 80 % of the assigned study 
supplements) ranged from 60 % to 63 % during the first three years of follow-up, with an additional 
13 % to 21 % of the participants taking at least half of their study pills. At the end of the trial, 76 % of 
the women were still taking the study supplements, of which 59 % were compliant. Dietary calcium 
intake during the trial remained stable, but intake from supplements increased by 100 mg/day in both 
groups. Supplementation with calcium and vitamin D resulted in an increased risk (17 %) of self-
reported clinically diagnosed kidney stones. Kidney stones were reported by 449 women in the 
supplemented group, as compared to 381 women in the placebo group (hazard ratio, 1.17; 95 % 
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CI 1.02-1.34). The Panel notes that although excluded by protocol design, 161 participants in the 
active arm and 172 in the placebo arm had a self-reported history of urinary tract stones and were 
included in the intention-to-treat analysis. It is unclear whether (and the extent to which) women with 
history of kidney stone formation contributed to the cases in each group. In a further analysis of the 
same study (Wallace et al., 2011), neither total calcium intake nor the use of calcium supplements at 
baseline were associated with the risk of kidney stones. The risk of kidney stones was not 
significantly different between the treatment and placebo groups when only subjects compliant with 
the study treatments were considered (hazard ratio: 1.21; 95 % CI 0.98-1.34). Confirmation of 
diagnosis upon hospital admission occurred in a small proportion of women (35 cases in each group) 
and was not significantly different between groups. The Panel notes that this study did not assess the 
relationship between dietary, supplemental (sum of both personal and trial supplements) or total 
calcium intakes in relation to the risk of kidney stone formation, but rather the effect of an additional 
amount of calcium (and vitamin D) over widely variable baseline calcium intakes from food and 
personal supplements (from <400 mg/day to >1,490 mg/day), and this additional amount of calcium 
was unrelated to the risk of developing kidney stones. The Panel also notes that additional calcium 
(and vitamin D) supplementation did not increase the risk of self-reported kidney stones in subjects 
who complied with the study treatment, or the proportion of women with objective diagnosis of 
kidney stones requiring hospital admission. The Panel considers that this study does not provide 
evidence for an increased risk of kidney stones which could be attributed to high calcium intakes.  
The Panel notes that calcium intakes up to about 2,400 mg/day have not been associated with an 
increased risk of chronic hypercalciuria or impaired kidney function, and that calcium intakes up to 
3,000 mg/day have not been associated with an increased risk of nepholithiasis in the general adult 
population. 
3.2.2.2. Infants  
One intervention study assessed calcium excretion in urine and renal function in relation to calcium 
intakes in infants. The formation of kidney stones in infants is rare. 
A double-blind RCT (Dalton et al., 1997; Sargent et al., 1999) was performed to investigate the 
efficacy of an iron-fortified (12.8 mg/L) cow’s milk-based formula with added calcium 
glycerophosphate (1,800 mg calcium/L, 1,390 mg phosphorus/L) vs. the same (control) formula 
without added calcium and phosphate (calcium 465 mg/L and phosphorus 317 mg/L) on the 
prevention of lead absorption in infants. The effects of the study formulas on calcium and iron 
metabolism were also assessed among other indicators of safety. Eligibility was tested 
pre-randomisation in 314 formula-fed healthy infants who consumed the test formula during a 
one-month run-in phase. Three infants developed hypercalciuria (calcium/creatinine >0.8 mg/mg) and 
were excluded from randomisation for this reason. A total of 103 eligible infants aged 3.5-6.0 months 
were randomised to consume either formula for nine months. Blood samples were obtained at baseline 
and at four and nine months, and urine samples at baseline, one, two, four, six and nine months for 
calcium and creatinine analysis. At the end of the intervention the mean age of the children was 
14 months. Eleven children dropped out in each of the study groups for various reasons. Calcium 
intake from formula was five times higher in the intervention group (n=41) than in controls (n=40) at 
baseline and at four and nine months (1,740±450, 1,710±460 and 1,560±700 mg/day vs 480±90, 
400±130 and 340±173 mg/day, respectively). Serum calcium concentrations did not differ between 
groups. One child in the control formula group had a serum calcium concentration >2.72 mmol/L after 
four months which returned to normal after nine months. There were no significant differences in 
urinary calcium/creatinine ratios between groups at baseline, or at four or nine months. Incidental 
hypercalciuria was observed in five infants in each group, which only persisted in a repeat sample in 
one subject of each group. Haematuria was not observed in any subject.  
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The Panel notes that in one small study, dietary calcium intakes up to about 1,750 mg/day for nine 
months did not increase the risk of hypercalcaemia, clinically significant hypercalciuria, or symptoms 
of kidney stones in infants. 
3.2.2.3. Children and adolescents 
In 2003, the SCF (2003) noted that no adverse effects of calcium citrate-malate supplements (500 to 
1,000 mg calcium over 1.5 to 3 years) or of extra dairy foods or foods fortified with milk extracts 
(700 to 820 mg/day extra calcium over one year) were reported in 217 children (from five intervention 
studies) between 6 and 14 years and between 6.6 and 11 years, respectively, in comparison to 
non-supplemented controls. Mean calcium intakes from diet in groups receiving calcium supplements 
were about 900-1,000 mg/day. The SCF considered these data as insufficient to derive a UL for 
children or adolescents. 
In a double-blind RCT aimed at investigating the role of calcium supplementation on lead poisoning, 
88 “moderately poisoned” children aged 1-6 years were randomised to consume calcium (dose 
adjusted to reach 1,800 mg/day from food and supplements) or placebo for three months. Data from 
67 children were available for analysis (35 in the calcium group). Calcium intake at enrolment was 
1,108±465 mg and 973±409 mg for the placebo controls and supplemented groups, respectively. 
Urinary calcium/creatinine ratios did not differ between children in the intervention (total calcium 
intake of 1,701±121 mg /day) and control (1,012±454 mg Ca/day) groups, and were 0.1±0.1 
throughout the study. Haematuria was not observed (Markowitz et al., 2004). 
The Panel notes that, in one small study of short duration, calcium intakes of about 1,800 mg/day for 
three months did not affect renal function in children aged 1-6 years. No new data are available for 
adolescents. 
3.2.3. Risk of cardiovascular disease 
Chronic hypercalcaemia can lead to calcification of soft tissues, particularly if phosphorus levels are 
also high, but no relationship between calcium intake and the occurrence of nephrocalcinosis or 
calcification of vascular tissue has been established in humans except in the presence of decreased 
kidney function. Coronary artery calcification has been described in patients with renal insufficiency 
on dialysis and treated with calcium-containing phosphate binders (Asmus et al., 2005; Block et al., 
2005; Goodman et al., 2000; Russo et al., 2007), but not in healthy subjects. 
It has been hypothesised that excess calcium intakes leading to chronic hypercalcaemia could increase 
the risk of cardiovascular events through arterial calcification. Arterial calcification has been 
associated with an increased risk of cardiovascular morbidity and mortality in men and women in a 
number of prospective cohort studies (Jacobs et al., 2010; Levitzky et al., 2008; Wilson et al., 2001; 
Wong et al., 2009).  
Few studies have investigated the relationship between calcium intake and vascular calcification in 
healthy subjects and none of these was designed for that purpose. 
In a RCT trial of two years duration in 163 healthy men (age 57±10 years), no difference in 
calcification of the coronary arteries or the abdominal aorta assessed by computed tomography (CT) 
was observed between subjects on calcium supplements (1,200 mg/day) and subjects on placebo (Van 
Pelt et al., 2009). Calcium intakes from diet were not reported. 
In contrast, in a retrospective analysis of a two-year RCT of similar size which investigated the effect 
of supplemental calcium (1,000 mg/day) and vitamin D3 (20 µg/day) given as fortified milk 
(vs. no supplemental milk) on bone mass in 167 men >50 years of age (Daly et al., 2006), men with 
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calcification of the abdominal aorta measured by CT at baseline and receiving the fortified milk 
showed a significantly greater progression of aortic calcification than controls (Daly et al., 2006). 
Baseline mean dietary calcium intake was about 900 mg/day and serum 25(OH)D was 75 nmol/L.  
In the Epidemiology of Coronary Artery Calcification study conducted between 1991 and 2008 
(Bhakta et al., 2009), 1,376 randomly selected asymptomatic adults of all ages were repeatedly 
examined by electron beam computed tomography for coronary artery calcification (CAC) or aortic 
valve calcification (AVC). A retrospective analysis was performed on the subgroup of 
257 participants (144 female) >60 years who had CAC or AVC at baseline and at least one follow-up 
measurement. None of the males and only 25 of the 144 female subjects reported taking calcium 
supplements (500-2,000 mg/day). The CAC and AVC scores at baseline or their progression rates 
over time (mean follow-up 3.7±0.9 years) were not significantly different between calcium 
supplement female users and non-users. The Panel notes that this study may have been underpowered 
for the CAC outcome.  
The Panel notes that the data available on the relationship between calcium intake and risk of vascular 
calcification in humans are inconsistent.   
A number of large prospective cohort studies have found a positive association between serum 
calcium concentrations and increased risk of myocardial infarction, stroke or death in the general 
adult population and in patients with coronary artery disease (Foley et al., 2008; Grandi et al., 2012; 
Jorde et al., 1999; Lind et al., 1997). However, these studies do not allow conclusions to be drawn on 
the relationship between dietary calcium intakes and cardiovascular disease (CVD) risk because 
calcium intakes were not reported.  
A systematic review (Chung et al., 2009) which investigated the relationship between calcium intakes 
(food and supplements) and incidence of cardiovascular (CV) disease (i.e., total, fatal and non-fatal 
CV events; total, fatal and non-fatal myocardial infarction and stroke) identified ten longitudinal 
cohort studies (Al-Delaimy et al., 2003; Ascherio et al., 1998; Bostick et al., 1999; Iso et al., 1999; 
Larsson et al., 2008; Marniemi et al., 2005; Umesawa et al., 2006; 2008; Van der Vijver et al., 1992; 
Weng et al., 2008), one nested case-control study (Ross et al., 1997), and no RCTs which had 
evaluated such a relationship. Except for two studies with a sample size of 755 (Marniemi et al., 
2005) and 1,340 (Van der Vijver et al., 1992) subjects, the cohorts included >17,700 and up to about 
44,000 subjects. Baseline calcium intakes were assessed by FFQs in all studies and were analysed as 
predictors of long-term cardiovascular outcomes. Calcium intake within the studied populations 
varied widely across studies. Mean intakes in the lowest and highest quintiles ranged from about 250 
and 667 mg/day in the Japan Collaborative Cohort (JACC) Study (Umesawa et al., 2006) to 876 and 
1,916 mg/day in a Finnish male cohort (Larsson et al., 2008). Calcium intakes in studies on Asian 
populations were generally low (Umesawa et al., 2006; 2008; Weng et al., 2008). Two studies 
addressed CV death in men and women separately with follow-ups of 9 and 28 years (Umesawa et al., 
2006; Van der Vijver et al., 1992); three studies assessed cardiac events (fatal and non fatal 
combined) either in both sexes together or in men with follow-ups of 10-13 years (Al-Delaimy et al., 
2003; Marniemi et al., 2005; Umesawa et al., 2008); cardiac death was analysed in four studies, 
separately in men and women, at 8, 9, 12 or 28 years of follow-up (Al-Delaimy et al., 2003; Bostick et 
al., 1999; Umesawa et al., 2008; Van der Vijver et al., 1992), and non-fatal cardiac events in one 
study in men with 12 years of follow-up (Al-Delaimy et al., 2003); six studies assessed total incidence 
of stroke in men, women, or both sexes combined with follow-ups of 8-14 years (Ascherio et al., 
1998; Iso et al., 1999; Larsson et al., 2008; Marniemi et al., 2005; Umesawa et al., 2008; Weng et al., 
2008); and two studies addressed fatal stroke in men and women separately with follow-ups of 10 and 
13 years (Ross et al., 1997; Umesawa et al., 2006). One study (the Iowa Women's Health Study, 
Bostick et al., 1999) found a significant association between calcium intake <696 mg/day and higher 
risk of ischemic heart disease death compared to an intake of >1,425 mg calcium/day in white women 
aged 55 to 69 years. A Japanese (Umesawa et al., 2008) and a Taiwanese (Weng et al., 2008) study in 
men and women (40-79 years and ≥40 years, respectively) found progressively lower risks for stroke 
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in subjects in higher quintiles of calcium intake in populations with relatively low calcium intakes, 
whereas one study in women (32-57 years) found significantly higher stroke risk in subjects with 
calcium intake <500 mg/day compared with women in the next two higher quintiles (Iso et al., 1999). 
No other associations between calcium intake (total, from food or from supplements) and risk of CVD 
(any outcome, men, women, or both sexes combined) were reported.  
Three additional prospective cohort studies on the relationship between calcium intakes and risk of 
CVD have been published.  
In the Kuopio Osteoporosis Risk Factor and Prevention Study (Pentti et al., 2009), 10,555 females 
aged 52-62 years without coronary heart disease (CHD) in 1994 were followed-up for seven years. 
Information about health events and supplemental calcium intake was obtained at baseline via 
questionnaires, whereas dietary calcium intakes were calculated from liquid milk products and cheese. 
Dietary calcium intakes in the 2,723 (25.8 %) users and the 7,832 non-users of calcium or calcium 
plus vitamin D supplements according to the 1994 questionnaire were 773±351 mg/day and 
818±404 mg/day, respectively. In age-adjusted analysis of the entire cohort, the hazard ratio (HR) for 
CHD was 1.14 (95 % CI 0.94–1.39) in calcium supplement users compared with non-users. The 
multivariate adjusted HR for supplement users compared to non users with respect to CHD was 
1.24 (95 % CI 1.02-1.52) for the total sample and 1.26 (95 % CI 1.01-1.57) for postmenopausal 
women. The Panel notes that calcium intakes from supplements were not reported.   
In the European Prospective Investigation into Cancer and Nutrition (EPIC) study (Li et al., 2012), 
23,980 participants aged 35-64 years with no history of major CV events were followed up for about 
11 years. Dietary calcium was assessed at baseline using a FFQ, whereas use of dietary supplements 
(including calcium) was checked by questionnaires at baseline and regularly during follow-up. 
Outcome measures were incidence of myocardial infarction, incidence of stroke, and CVD mortality. 
A total of 354 cases of myocardial infarction, 260 cases of stroke and 267 cases of CV death were 
documented during follow-up. Between 3 and 4 % of participants reported use of calcium 
supplements (either alone or in combination with other vitamins and minerals), but doses of 
supplemental calcium were not reported. Mean dietary calcium intake at baseline was 766 mg/day in 
supplement non-users and about 820 mg/day in supplement users. After adjustment for potential 
confounders, none of the linear trend tests were statistically significant. A statistically significant 
inverse association was only found between total dietary calcium intake and risk of myocardial 
infarction for the third (820 mg/day) quartile compared with the lowest (513 mg/day) quartile 
(HR 0.69; 95 % CI 0.50-0.94) in both sexes combined. The association was also significant for 
women (HR 0.43; 95 % CI 0.22-0.82), but not for men. Users of calcium supplements had a 
statistically significantly increased risk of myocardial infarction in comparison with non-users of any 
supplements (HR 1.86; 95 % CI 1.17-2.96). This association was more pronounced for calcium-only 
supplement users (HR 2.39; 95 % CI 1.12-5.12), and related to most recent but not to cumulative 
calcium supplementation. No significant association was found between calcium supplementation and 
risk of either stroke or overall CVD mortality. 
In a subsequent publication (Mursu et al., 2011) of the Iowa Women’s Health Study (Bostick et al., 
1999), 38,772 women aged 55-69 years were followed-up for 19 years. Diet was assessed using a FFQ 
in 1986 and 2004, and the use of supplemental calcium by a specific questionnaire in 1986, 1987, 
1989, 1992, 1997 and 2004. After adjustment for confounders, use of calcium-containing supplements 
was associated with a significantly lower rate of total mortality (HR 0.91; 95 % CI 0.88-0.94) and 
cardiovascular mortality (HR 0.87; 95 % CI 0.82-0.92). The inverse association between supplemental 
calcium and total mortality was not significant at the highest doses of supplemental calcium 
(>1,300 mg calcium/day). The Panel notes that dietary (and thus total) calcium intakes were not 
reported in this follow-up analysis.  
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The Panel notes that calcium intakes up to about 2,000 mg/day from food and supplements have not 
generally been associated with an increased risk of CV events in a high number of large prospective 
cohort studies.  
No RCTs specifically designed to investigate the effects of supplemental calcium on CVD risk are 
available.  
In a systematic review and meta-analysis (Wang et al., 2010), four RCTs which reported on the 
occurrence of CV events with calcium supplementation versus placebo were identified (Baron et al., 
1999; Bolland et al., 2008; Prince et al., 2006; Reid et al., 2008). The study by Baron et al., (1999) 
reported similar proportions of subjects hospitalised for cardiac disease (10 % vs. 11 %) or stroke 
(2 % vs. 3 %) among those who received 1,200 mg/day of supplemental calcium (n=464) and those 
who received placebo (n=466) for four years (mean calcium intakes from diet 880 mg/day). Prince et 
al., (2006) also found similar rates of CHD in women receiving supplemental calcium (n=730) or 
placebo (n=730) for five years (mean calcium intakes from diet 915 mg/day). Consumption of calcium 
supplements (1,000 mg/day; n=732) for five years did not increase the risk of myocardial infarction, 
stroke or composite CVD endpoint (myocardial infarction, stroke, sudden death) in post-menopausal 
women (mean calcium intakes from diet 860 mg/day) when unreported events obtained from a 
national database were included in the analysis (Bolland et al., 2008). One trial in men of two years 
duration found significantly more self-reported composite CV events in the calcium supplemented 
group (600 mg or 1,200 mg/day; n=216) than in the placebo group (n=107) (Reid et al., 2008). The 
Panel notes the low number of cases reported in each group (three in the calcium and one in the 
placebo groups). The pooled relative risk of CVD for all trials combined was 1.14 (95 % 
CI 0.92-1.41). The Panel considers that this meta-analysis does not show an increased risk of CV 
events with calcium supplements of 600 to 1,200 mg/day consumed for two to five years in addition 
to dietary calcium intakes of about 900 mg/day. 
A systematic review and meta-analysis (Bolland et al., 2010) considered 11 double-blind RCTs 
(Baron et al., 1999; Bolland et al., 2008; Bonithon-Kopp et al., 2000; Bonnick et al., 2007; Dawson-
Hughes et al., 1990; Grant et al., 2005; Lappe et al., 2007; Lappe and Heaney, 2008; Prince et al., 
2006; Reid et al., 1993, 1995; Reid et al., 2006; Reid et al., 2008; Riggs et al., 1998) which used 
calcium supplements at doses 500 mg/day for more than one year in subjects aged 40 years at 
baseline for the prevention or treatment of osteoporosis or colorectal adenomas. Trials were excluded 
when calcium plus vitamin D were compared to placebo. The studies included collectively about 
12,000 subjects (6,116 in the calcium supplemented groups; 5,805 in the placebo groups) and the 
outcome measures of interest were myocardial infarction, stroke, sudden death, and death from all 
causes. Only the four RCTs included in the meta-analysis by Wang et al. (2010) had reported on these 
outcomes. Baseline age of participants ranged from 56 to 77 years and trial duration from two to five 
years. Doses of supplemental calcium ranged from 500 to 2,000 mg/day in addition to average dietary 
calcium intakes of 400-1,240 mg/day. Calcium supplementation did not increase the risk for any 
outcome in any of the individual studies, or the risk of myocardial infarction, stroke, and sudden death 
combined, the risk of death, or the risk of stroke in the meta-analyses performed. Allocation to 
calcium supplementation was associated with an increased risk of myocardial infarction (RR 1.27, 
95 % CI 1.01-1.59). One trial (Grant et al., 2005) accounted for 66 % of the subjects and for >50 % of 
the CV events in the meta-analysis. The compliance rate with the study pills in that study was only 
54.5 % (about 45 % in the calcium arms), and the clinical characteristics of participants who did and 
did not return the completed health questionnaires used for the allocation of events were unknown, 
which may have introduced bias in between-group comparisons. The Panel notes that cardiovascular 
events, including myocardial infarction, were not end points in a number of trials but the events were 
rather attributed on the basis of self-reported health questionnaires and were not verified. The Panel 
also notes that event frequency and differences in the number of events between the calcium and 
placebo groups were small, and that the use of multiple end points without adjustment of the level of 
significance for multiple testing increases the likelihood of chance findings. The Panel considers that 
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this meta-analysis does not show an increased risk of CV events (myocardial infarction or stroke) with 
calcium supplements of 500 to 2,000 mg/day consumed for two to five years in addition to dietary 
calcium intakes of 400-1,240 mg/day. 
The same authors (Bolland et al., 2011) updated the above mentioned meta-analysis by including data 
from two study arms comparing calcium and vitamin D supplements against placebo (Grant et al., 
2005; Lappe et al., 2007), and from a sub-sample of subjects participating in the WHI intervention 
trial (supplementation with calcium and vitamin D versus placebo) described in Section 3.2.2.1. 
In that study, no effect of calcium (and vitamin D) supplements on confirmed cases of myocardial 
infarction, stroke, or coronary heart disease death, which were pre-specified secondary efficacy 
outcomes of the study, had been reported by the authors (Hsia et al., 2007). In subgroup analyses, 
women with higher total calcium intake (diet plus supplements) at baseline were not at higher risk for 
coronary events or stroke if assigned to the active calcium/vitamin D group. In the meta-analysis by 
Bolland et al. (2011), only data from subjects not taking personal supplements at baseline were 
considered. The Panel notes that the reasons for the selection are unclear, and that subjects were not 
randomised on the basis of taking personal supplements. The Panel also notes that the additional data 
considered (supplementation with calcium plus vitamin D against placebo) does not provide 
information about the risk associated with supplemental calcium intakes per se. The Panel considers 
that this meta-analysis suffers from the same limitations as the previous meta-analysis by the same 
authors (Bolland et al., 2010), and that it does not provide additional information about the 
relationship between calcium intakes and risk of CVD. 
The Panel considers that long-term calcium intakes from diet and supplements up to 
2,500-3,000 mg/day are not associated with an increased risk of cardiovascular disease in adults. 
3.2.4. Prostate cancer 
The majority of epidemiological studies and the few RCTs which have reported cancer as an outcome 
found an inverse or no association between calcium intakes from food and/or supplements and the risk 
of cancer (incidence and mortality), with the exception of prostate cancer (Chung et al., 2009; IoM, 
2011; WCRF/AICR, 2007).  
The report from the World Cancer Research Fund/American Institute for Cancer Research 
(WCRF/AICR, 2007), reviewed nine prospective cohort studies (Baron et al., 2005; Berndt et al., 
2002; Chan et al., 2000; Chan et al., 2001; Giovannucci et al., 1998; Laaksonen et al., 2004; Platz et 
al., 2004; Rodriguez et al., 2003; Schuurman et al., 1999; Tseng et al., 2005), 12 case-control studies 
(Chan et al., 1998; Du et al., 1997; Hayes et al., 1999; Hodge et al., 2004; Kaul et al., 1987; Key et al., 
1997; Ohno et al., 1988; Oishi et al., 1988; Ramon et al., 2000; Tavani et al., 2001; Tavani et al., 
2005; Tzonou et al., 1999; Vlajinac et al., 2001; Vlajinac et al., 1997; Walker et al., 2005) and two 
ecological studies (Boing et al., 1985; Liaw et al., 2003) which investigated the association between 
calcium intake and risk of prostate cancer. A positive association between calcium intake and risk of 
prostate cancer was reported in three cohort studies (Chan et al., 2001; Giovannucci et al., 1998; 
Tseng et al., 2005), one case-control study (Vlajinac et al., 2001) and one ecological study (Boing et 
al., 1985), whereas no significant association was observed in the remaining studies. An increased risk 
of advanced/aggressive prostate cancer was also associated with increased intakes of milk and dairy 
products in one (Giovannucci et al., 1998; 2006) out of the four cohort studies which reported on this 
outcome. The WCRF/AICR (2007) concluded that there was a “probable” association between diets 
high in calcium and prostate cancer risk.  
Chung et al. (2009) reviewed 12 cohort studies that reported on the association between calcium 
intake and the risk of prostate cancer (Baron et al., 2005; Chan et al., 2001; Giovannucci et al., 2006; 
Koh et al., 2006; Kurahashi et al., 2008; Mitrou et al., 2007; Park et al., 2007a; 2007b; Rodriguez et 
al., 2003; Rohrmann et al., 2007; Schuurman et al., 1999; Tseng et al., 2005). The incidence of 
prostate cancer in these studies ranged from 0.008 to 0.10. Total calcium intake ranged from 
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<500 mg/day to ≥2,000 mg/day and the time between dietary assessment and the diagnosis of prostate 
cancer varied from 1 to 17 years. Seven studies did not find an association between calcium intake 
and the risk of prostate cancer (Baron et al., 2005; Koh et al., 2006; Kurahashi et al., 2008; Park et al., 
2007a; 2007b; Rohrmann et al., 2007; Schuurman et al., 1999), whereas the remaining five studies 
reported a higher risk associated with higher (vs. lower) calcium intakes. The higher and lower 
calcium intakes ranged from 921 to >2,000 mg and from 455 to 1,000 mg/day, respectively.  
One multicentre RCT (Baron et al., 2005) which investigated the efficacy of calcium supplementation 
in the prevention of colorectal carcinomas also assessed the risk of prostate cancer as a secondary 
outcome. Men (mean age 61.8 years) received either 1,200 mg of calcium (n=327) or placebo (n=327) 
daily for four years and were followed for up to 12 years for prostate cancer diagnosis. Dietary 
calcium intake at baseline was comparable in the two groups (about 800 mg/day). Over the entire 
study period, the risk for prostate cancer was not significantly different in the calcium group 
compared to the placebo (rate ratio, 0.83; 95 % CI 0.52–1.32). Total calcium intakes were not 
associated with prostate cancer risk. 
The Panel notes that a number of case-control (one out of 12) and prospective cohort studies (five out 
of 12, three of which were of good quality) have reported an increased risk of prostate cancer with 
total calcium intakes of 1,000 to >2,000 mg/day compared to intakes ranging from 500 to 
<1,000 mg/day. However, the Panel also notes that these studies were uncontrolled for factors other 
than calcium and which may have been responsible for the effect, and that the only RCT which 
reported on this outcome showed no effect of calcium supplementation at doses of 1,200 mg/day (up 
to about 2,000 mg/day of total calcium) on the risk of prostate cancer.  
The Panel considers that long-term calcium intakes from diet and supplements above 2,000 mg/day 
are not associated with an increased risk of prostate cancer. 
3.2.5. Interactions between calcium and dietary minerals 
Calcium has been shown to interfere with both iron and zinc absorption in short term trials or 
single-dose experiments. This effect has not been observed in long-term observational and 
intervention studies at dietary calcium intakes in the range of current recommendations or at 
supplemental calcium intakes up to 2,000 mg/day in adults (SCF, 2003). 
The Panel notes that no new data have become available since 2003 on this outcome.  
4. Dose response assessment and derivation of a Tolerable Upper Intake Level  
4.1. Adults 
The SCF (2003) based the derivation of a UL for calcium on the evidence of different intervention 
studies of long duration, some of which were placebo controlled, in which total daily calcium intakes 
of 2,500 mg from both diet and supplements were tolerated without adverse effects. Because of the 
abundance of data, the application of an uncertainty factor was considered unnecessary. A UL of 
2,500 mg of calcium per day from all sources was proposed for adults, and for pregnant and lactating 
women.  
A number of placebo controlled human intervention studies in adults published since then also show 
that total daily calcium intakes of 2,500 mg from both diet and supplements are tolerated without 
adverse effects.  
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The Panel notes that new case reports have become available on consumption of calcium supplements 
and the CAS/MAS syndrome. However, the Panel considers that no dose-response relationships can 
be derived from these.  
The Panel considers that no relationship has been established between long-term calcium intakes from 
diet and supplements and increased risk of nephrolithiasis, cardiovascular disease or prostate cancer.  
The Panel proposes a UL of 2,500 mg/day of calcium from all sources. 
4.2. Pregnant and lactating women 
The UL for pregnant and lactating women established by the SCF (2003) was the same as for adults.  
The Panel notes that no new data have become available since 2003 for this population subgroup.  
The Panel proposes a UL of 2,500 mg/day of calcium from all sources. 
4.3. Infants 
In 2003, the SCF concluded that the data available were insufficient to establish a UL for infants.  
The Panel notes that no new data have become available for this population subgroup since 2003. 
The Panel concludes that the data are insufficient to establish a UL for infants.  
4.4. Children and adolescents 
In 2003, the SCF concluded that the data available were insufficient to establish a UL for children and 
adolescents.  
The Panel notes that calcium intakes of about 1,800 mg/day did not affect renal function in children 
aged 1-6 years in one small, short-term (three month) RCT (Markowitz et al., 2004). However, the 
Panel considers that these data are not sufficient for establishing a UL for children or adolescents.  
The Panel concludes that the data are insufficient to establish a UL for children or adolescents.  
5. Characterisation of the risk 
Data from European populations indicate that intakes of calcium in high consumers among adult 
males can be close to the UL.   
Although available data do not allow the setting of a UL for infants, children or adolescents, no risk 
has been identified with highest current levels of calcium intake in these age groups. 
CONCLUSIONS  
The Panel proposes a UL for calcium of 2,500 mg for adults, and for pregnant and lactating women. 
The Panel considers that the available data are insufficient to set a UL for infants, children or 
adolescents.  
Data from European populations indicate that intakes of calcium in high consumers among adult 
males can be close to the UL. Although available data do not allow the setting of a UL for infants, 
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children or adolescents, no risk has been identified with highest current levels of calcium intake in 
these age groups. 
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APPENDICES 
A.  INTAKE OF CALCIUM AMONG ADULTS IN EUROPEAN COUNTRIES 
Nutrient 







Population / Fortified 
foods included or excluded mean median P75 P95 P97.5 
Food Women Austria 
(Elmadfa et al., 
2009) 24-hour recall 426 < 25 > 35 pregnant 2nd trimester 919.0 
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25 pregnant 2nd trimester 798.0 
    





35 pregnant 2nd trimester 919.0 
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35 > 35 pregnant 2nd trimester 1,078.0 
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2010) 
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(Tetens et al., 
2011) 
7-day record and interview (data 
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Tolerable Upper Intake Level of calcium 
 
EFSA Journal 2012;10(7):2814 32 
Nutrient 







Population / Fortified 
foods included or excluded mean median P75 P95 P97.5 
Food Women Italy 
(Sette et al., 
2010) Consecutive 3-day food record 1,245 
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Nutrient 







Population / Fortified 





(De Vriese et 
al., 2006) Two 24-hour recall 873   19   59   813.3   978.0 
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(Dufour et al., 
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Supplements Women Austria 
(Elmadfa et al., 
2009) 
Quantitative consumption 
frequency questionnaire 28   18   65 
Assessment of the 
consumption of 
supplements among 282 
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Users of calcium 
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Users of calcium 
supplements 409.0     1,200.0 
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Nutrient 







Population / Fortified 
foods included or excluded mean median P75 P95 P97.5 
Supplements Men Austria 
(Elmadfa et al., 
2009) 
Quantitative consumption 
frequency questionnaire 21   18   65 
Assessment of the 
consumption of 
supplements among 282 
adults in all Austria 
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Users of calcium 
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Users of calcium 
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Food and 
supplements Women Denmark 
(Tetens et al., 
2011) 
7-day record and interview (data 
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Nutrient 







Population / Fortified 
foods included or excluded mean median P75 P95 P97.5 
Food and 
supplements Men Denmark 
(Tetens et al., 
2011) 7-day record and interview 587   18   49 Supplements users 1,228.0     2,029.0 
 
     




(Paturi et al., 
2008) 
48-hour recall and two 3-day 
records for the usual intakes over 
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NB: white: less than ~50 years. grey: over ~50 years 
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B.  INTAKE OF CALCIUM AMONG CHILDREN IN EUROPEAN COUNTRIES 
Nutrient 






Population / Fortified 
foods included or 







(de Boer et al., 
2006) 
2-day record 
(independent days)  333 0.75 
 




     
306 1 
 





supplements Girls Finland 
(Kyttälä et al., 
2008; 2010) 3-day record 198 1   1 
non breast-fed infants 
genetically at-risk of type 
1 diabetes 696.0   885.0       
Food and 
supplements Boys Finland 
(Kyttälä et al., 
2008; 2010) 3-day record 257 1 
 
1 
non breast-fed infants 
genetically at-risk of type 
1 diabetes 670.0 
 
886.0 
   
Food Girls Denmark 
(Andersen et 
al., 1996) 7-day record 149 1   3   996.0       1,325.0   
    
The 
Netherlands 
(Ocke et al., 
2008) 
2-day record 
(independent days) 313 2   3   734.0       1,089.0   
Food Boys Denmark 
(Andersen et 
al., 1996) 7-day record 129 1   3   910.0       1,359.0   
    
The 
Netherlands 
(Ocke et al., 
2008) 
2-day record 





(Manios et al., 
2008) 
3-day record (weighed 
food records and 24 h 
recall or food diaries) 2,317 1   5 
Non under-reporters. 
Possible inclusion of 
supplements not 
mentioned 1,024.0     1,392.0     
    Italy 
(Sette et al., 
2010) 
Consecutive 3-day 
food records 52 0 < 3 Including fortified food 664.0       1,070.0   
    
The 
Netherlands 
(de Boer et al., 
2006) 
2-day record 
(independent days)  302 1.5   1.5 Including fortified food 866.0     1,082.0     
    
United 
Kingdom 
(Bates et al., 
2011) 4-day food diary 219 1.5   3   773.0         1,365.0 
Food and 
supplements Girls Finland 
(Kyttälä et al., 
2008; 2010) 3-day record 118 2   2 
Children genetically at-
risk for type 1 diabetes 870.0   1,019.0       
          235 3   3   881.0   1,062.0       
    
The 
Netherlands 
(Ocke et al., 
2008) 
2-day record 
(independent days) 313 2   3   740.0       1,099.0   
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Nutrient 






Population / Fortified 
foods included or 
excluded mean median P75 P90 P95 P97.5 
Food and 
supplements Boys Finland 
(Kyttälä et al., 
2008; 2010) 3-day record 112 2   2 
Children genetically at-
risk for type 1 diabetes 844.0   1,037.0       
          236 3   3   925.0   1,109.0       
    
The 
Netherlands 
(Ocke et al., 
2008) 
2-day record 








(Bates et al., 
2011) 4-day food diary 219 1.5   3   775.0         1,365.0 








(van Rossum et 
al., 2011) 
Two non-consecutive 

























(van Rossum et 
al., 2011) 
Two non-consecutive 













(Pedersen et al., 










(Sette et al., 
2010) 
Consecutive 3-day 
food records 52 3 < 10 Including fortified food 749.0 





(Flynn et al., 










(Flynn et al., 





   
1,134.0 
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Nutrient 






Population / Fortified 
foods included or 





(Flynn et al., 
2009) 
24-hour recall and 
food frequency 
questionnaire, a 
second 24-hour recall 
in 25-30 % of the 











(Flynn et al., 
2009) 
2-day record 
(independent days) 639 4 
 
6 Including fortified food 716.0 






(Bates et al., 





    
1,339.0 
Food and 
supplements Girls Finland 
(Kyttälä et al., 
2008; 2010) 3-day record 247 4   4 
Children genetically at-
risk for type 1 diabetes 930.0   1,089.0       












(van Rossum et 
al., 2011) 
Two non-consecutive 


















supplements Boys Finland 
(Kyttälä et al., 
2008; 2010) 3-day record 307 4   4 
Children genetically at-
risk for type 1 diabetes 983.0           










(van Rossum et 
al., 2011) 
Two non-consecutive 














(Flynn et al., 























(Flynn et al., 





   
1,134.0 
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Nutrient 






Population / Fortified 
foods included or 






(Flynn et al., 
2009) 
24-hour recall and 
food frequency 
questionnaire, a 
second 24-hour recall 
in 25-30 % of the 
sample 723 4 
 
10 Including fortified food 898.0 






Barbieri et al., 





   
1,330.0 
 






   
1,537.0 
 












(Flynn et al., 
2009) 
2-day record 





   
1,165.0 
 
     
639 4 
 
6 Including fortified food 811.0 
   
1,247.0 
 
    
United 
Kingdom 
(Bates et al., 
2011) 4-day food diary 423 4   10   804.0         1,339.0 
Food Girls Denmark 
(Pedersen et al., 
2010) 7-day record 134 14   17   966.0       1,699.0   




Alliance), b) 7-day record 217 13   17   734.0       1,376.0 1,554.0 
    Italy 
(Sette et al., 
2010) 
Consecutive 3-day 
food records 139 10 < 18 Including fortified food 770.0       1,306.0   
    
The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 
24-hour dietary recalls 354 14   18     876.0     1,435.0   
Tolerable Upper Intake Level of calcium 
 
EFSA Journal 2012;10(7):2814 41 
Nutrient 






Population / Fortified 
foods included or 
excluded mean median P75 P90 P95 P97.5 
Food Boys Denmark 
(Pedersen et al., 
2010) 7-day record 101 14   17   1,288.0       2,245.0   




Alliance), b) 7-day record 224 13   17   1,063.0       1,905.0 2,047.0 
    Italy 
(Sette et al., 
2010) 
Consecutive 3-day 
food records 108 10 < 18 Including fortified food 892.0       1,435.0   
    
The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 





(De Vriese et 
al., 2006) Two 24-hour recall 806 15   18   787.9   966.0       
    Germany 
(Flynn et al., 
2009) 3-day record 1,272 12   17 
 
1,337.0       2,400.0   
    Spain 
(Flynn et al., 
2009) 
24-hour recall and 
food frequency 
questionnaire, a 
second 24-hour recall 
in 25-30 % of the 
sample 1,137 11   17 
 
878.0       1,231.0   
    
United 
Kingdom 
(Bates et al., 
2011) 4-day food diary 453 11   18   785.0         1,522.0 
Supplements Girls Germany (MRI, 2008) 
24-hour recall + 
Dietary History 34 14   18   189.0       1,000.0   
Supplements Boys Germany (MRI, 2008) 
24-hour recall + 





(van Rossum et 
al., 2011) 
Two non-consecutive 





(van Rossum et 
al., 2011) 
Two non-consecutive 
24-hour dietary recalls 352 14   18     1,010.0     1,692.0   
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Nutrient 






Population / Fortified 
foods included or 






(Flynn et al., 
2009) 3-day record 1,272 12   17   1,350.0       2,422.0   
          1,272 12   17 Including fortified food 1,396.0       2,515.0   




Alliance), b) 7-day record 441 13   17   906.0       1,657.0   
    Poland 
(Flynn et al., 
2009) 24-hour recall 581 11   17   1,398.0       2,975.0   
    Spain 
(Flynn et al., 
2009) 
24-hour recall and 
food frequency 
questionnaire, a 
second 24-hour recall 
in 25-30 % of the 
sample 1,137 11   17 Including fortified food 900.0       1,267.0   
    
United 
Kingdom 
(Bates et al., 
2011) 4-day food diary 453 11   18   786.0         1,522.0 
NB: First white section: infants. First grey section: ~1-3 years. Second white section: older children. Second grey section: ~teenagers 
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GLOSSARY AND ABBREVIATIONS 
1,25-(OH)2-D 1,25-dihydroxycholecalciferol 
25(OH)D  25-Hydroxy-vitamin D 
AVC  Aortic valve calcification 
BMI  Body Mass Index 
CAC  Coronary artery calcification 
CAS  Calcium-alkali-syndrome 
CaSR  Calcium-sensing receptor 
CHD  Coronary heart disease 
CI  Confidence interval 
CT  Computed tomography 
CV  Cardiovascular 
CVD  Cardiovascular disease 
CYP  Cytochrome  
PEPIC  European Prospective Investigation into Cancer and Nutrition 
FFQ  Food frequency questionnaire 
HR  Hazard ratio 
IoM  Institute of Medicine 
IU  International Unit 
JACC  Japan Collaborative Cohort 
LOAEL Lowest-observed-adverse-effect-level 
MAS  Milk-alkali syndrome 
NCX1  Na/Ca Exchanger 1 
NOAEL No observable adverse effect level 
OMIM  Online Mendelian Inheritance in Man 
PMCA  Plasma-membrane Ca-ATPase 
PTH  Parathyroid hormone 
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RCT  Randomised controlled trial 
RR  Relative risk 
SCF  Scientific Committee on Food 
TRPV  Transient Receptor Potential Vanilloid 
UL  Tolerable Upper Intake Level 
VDR  Vitamin D receptor 
WCRF/AICR World Cancer Research Fund/American Institute for Cancer Research 
WHI  Women’s Health Initiative 
